Download presentation
Presentation is loading. Please wait.
Published bySharon Chapman Modified over 6 years ago
1
A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response Ramesh Rengan, MD, PhD, Rosemarie Mick, MS,, Daniel Pryma, MD, Mark A. Rosen, MD, PhD, Lilie L. Lin, MD, Amit M. Maity, MD, PhD, Tracey L. Evans, MD, James P. Stevenson, MD, Corey J. Langer, MD, John Kucharczuk, MD, Joseph Friedberg, MD, Susan Prendergast, BS, RN, Tiffany Sharkoski, BA, Stephen M. Hahn, MD Journal of Thoracic Oncology Volume 7, Issue 4, Pages (April 2012) DOI: /JTO.0b013e aa6 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 Study design. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e aa6) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
3
Figure 2 Example of pretreatment and posttreatment positron emission tomography (PET)/computed tomography (CT) scan showing a complete metabolic response to chemoradiotherapy and nelfinavir. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e aa6) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
4
Figure 3 Waterfall plot of best response by RECIST of all 12 response-evaluable patients receiving concurrent chemo-radiotherapy and nelfinavir. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e aa6) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.